Abstract
The present disclosure provides interleukin-36 (IL-36) cytokine (e.g., IL-36γ) expressing oncolytic viruses, and compositions comprising thereof. The present disclosure further provides methods of using said oncolytic viruses and compositions for treating cancer, and for improving a subject's responsiveness to an immunomodulatory agent.
Full Text
What is claimed is:
The present disclosure provides interleukin-36 (IL-36) cytokine (e.g., IL-36γ) expressing oncolytic viruses, and compositions comprising thereof. The present disclosure further provides methods of using said oncolytic viruses and compositions for treating cancer, and for improving a subject's responsiveness to an immunomodulatory agent.
Timeline
Filed
03/27/2026Published
07/30/2026Granted
Not AvailableIPC Codes(8)
A61K 38/20:Interleukins
A61K 35/15:Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells (therapeutic combinations of antibodies, or fragments thereof, and blood-derived cells A61K 39/00; cellular immunotherapy A61K 40/00)
A61K 35/17:Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (cellular immunotherapy A61K 40/00)